



MICHELLE LUJAN GRISHAM
Governor

DR. TRACIE C. COLLINS, M.D.
Secretary-Designate

NEW MEXICO HEALTH ALERT NETWORK (HAN)

ALERT

January 14, 2021

NMDOH Issues Updated Application for Non-Hospital Use of Monoclonal Antibody Infusions to Include Case by Case Approval of Immediate Use Compounding of Bamlanivimab

To further support continued expansion of out of hospital administration of lifesaving COVID therapeutics, the New Mexico Department of Health today issued an updated application for non-hospital use of monoclonal antibody infusions which includes language of the existing allowances for immediate use compounding of Bamlanivimab on a case by case approval basis.

Early evidence suggests that monoclonal antibodies for COVID-19 may prevent medical office visits or hospitalizations. Bamlanivimab and REGN-COV2 are approved for outpatient usage. Administration in non-hospital settings may help reduce hospital overflow and improve access to care for New Mexicans. The products must be prepared in accordance with the Emergency Use Authorization and current United States Pharmacopeia (USP) 797 sterile compounding practices, and when possible by a sterile compounding pharmacy licensed by New Mexico Board of Pharmacy. *In cases where utilizing a sterile compounding pharmacy subjects the patient to additional risk due to delays in therapy, immediate-use compounding of Bamlanivimab may occur.* Compounding of REGN-COV2 will be limited to sterile compounding pharmacies due to the potential for medication errors associated with the product packaging.

Additional references are included in the updated application. Questions should be directed to DOH-PHARMACY@state.nm.us

EPIDEMIOLOGY AND RESPONSE

1190 St. Francis Drive, N1320 • Santa Fe, New Mexico • 87502-6110
(505) 827-0006 • FAX: (505) 827-2110 • www.nmhealth.org